Neurocrine biosciences presents interim data demonstrating robust and sustained improvements in chorea associated with huntington's disease through week 104 irrespective of antipsychotic use

Kinect®-hd2 is the first prospective clinical trial to include patients taking antipsychotic medication in a study evaluating a vesicular monoamine transporter 2 (vmat2) inhibitor for the treatment of huntington's disease chorea findings presented at the 2024 mds international congress of parkinson's disease and movement disorders® san diego , sept. 30, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced interim results from the ongoing open-label kinect®-hd2 study of ingrezza® (valbenazine) capsules for the long-term treatment of adults with chorea associated with huntington's disease.
NBIX Ratings Summary
NBIX Quant Ranking